Beyond HIV-1, BIT225 is an important asset as it demonstrates the robustness of Biotron’s approach to antiviral drug development and that the Company can generate clinically safe drugs with activity against a new class of viral protein targets. The underwritten funding will enable the Company to advance the development of other promising compounds within the its proprietary compound library that have been shown to have activity against other serious viral diseases including Hepatitis C, Hepatitis B, Dengue and others. In turn, this will enable the Company to attract a commercial partner for these applications within the Company’s antiviral platform.
Good luck
- Forums
- ASX - By Stock
- BIT
- Ann: Biotron Secures $4.7 Million Underwriting Agreement
Ann: Biotron Secures $4.7 Million Underwriting Agreement, page-9
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.0¢ |
Change
0.001(5.26%) |
Mkt cap ! $18.94M |
Open | High | Low | Value | Volume |
2.0¢ | 2.1¢ | 2.0¢ | $34.45K | 1.717M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 1537498 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 2245665 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1537498 | 0.019 |
10 | 1700748 | 0.018 |
10 | 2417276 | 0.017 |
12 | 1659350 | 0.016 |
6 | 765000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 2245665 | 5 |
0.022 | 1107935 | 5 |
0.023 | 1299422 | 3 |
0.024 | 153949 | 2 |
0.025 | 223000 | 3 |
Last trade - 14.20pm 09/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online